Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer

Clinical Breast Cancer

Volumn 8, Issue 2, 2008, Pages 155-161

  Kirk, Margaret C ^a   Hudis, Clifford A ^b  

^a Y ME National Breast Cancer Organization   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Anastrozole; Aromatase inhibitors; Estrogen receptor; Exemestane; Letrozole; Minority population; Tamoxifen; Treatment adherence

Indexed keywords

ANASTROZOLE; ANTIDEPRESSANT AGENT; AROMATASE INHIBITOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; MEGESTROL ACETATE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADULT; AGED; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; FATIGUE; FEMALE; HEALTH CARE COST; HEALTH CARE PERSONNEL; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PATIENT COUNSELING; SELF REPORT; SEXUAL DYSFUNCTION; SKIN MANIFESTATION;

EID: 43249126529     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2008.n.016     Document Type: Article

References (34)